Omrix Biopharmaceuticals, Inc. Announces New Strategic Product Development Programs

NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, today announced two new strategic product development programs in anti adhesion and spine utilizing its fibrin sealant technology.

Back to news